News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS JANUARY 18, 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Monday, January 18, 2021
Breast Cancer Awareness Month: How Care Has Transformed In 2020
During Breast Cancer Awareness Month, read this recent article by VP Business Development and Marketing, Tlalit Bussi Tel-Tzure, sharing her firsthand insights on how the
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
Thailand, with a Population of 70 million People, Joins Other Significant Territories Japan and Singapore That will Benefit From IceCure’s Cryoablation Products. Learn more
IceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million
Recently Reported Preliminary First-Half 2020 Sales Were x3 Higher than Same Period in 2019, Demonstrating Significant Growth as Cryoablation Technology Continues to Gain Global Awareness.
IceCure shares first published results using the Prosense cryoablation system in kidney cancer
“None of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success.” The full research was published
COVID-19 Pandemic: Now is the Time to Embrace Healthcare Innovation by Tlalit Bussi
In this article, IceCure’s VP Business Development and Marketing, Tlalit Bussi Tel-Tzure’s discusses healthcare innovation in the time of COVID-19. The healthcare landscape has forever
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS JANUARY 18, 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Monday, January 18, 2021
Breast Cancer Awareness Month: How Care Has Transformed In 2020
During Breast Cancer Awareness Month, read this recent article by VP Business Development and Marketing, Tlalit Bussi Tel-Tzure, sharing her firsthand insights on how the
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
Thailand, with a Population of 70 million People, Joins Other Significant Territories Japan and Singapore That will Benefit From IceCure’s Cryoablation Products. Learn more
IceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million
Recently Reported Preliminary First-Half 2020 Sales Were x3 Higher than Same Period in 2019, Demonstrating Significant Growth as Cryoablation Technology Continues to Gain Global Awareness.
IceCure shares first published results using the Prosense cryoablation system in kidney cancer
“None of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success.” The full research was published
COVID-19 Pandemic: Now is the Time to Embrace Healthcare Innovation by Tlalit Bussi
In this article, IceCure’s VP Business Development and Marketing, Tlalit Bussi Tel-Tzure’s discusses healthcare innovation in the time of COVID-19. The healthcare landscape has forever